Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

W. Kruit · SciRah

Researcher profile · Semantic Scholar

W. Kruit

Share profile

W. Kruit — researcher profile on SciRah

h-index: 41
Works: 130
Citations: 7,242

Most-cited papers

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.
C. Lamers, S. Sleijfer, A. Vulto, W. Kruit +5 more
2006Journal of Clinical Oncology915 citations
Semantic Scholar
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
A. Eggermont, S. Suciu, M. Santinami, A. Testori +12 more
2008The Lancet539 citations
Semantic Scholar
Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
Fernando Ulloa-Montoya, J. Louahed, B. Dizier, O. Gruselle +7 more
2013Journal of Clinical Oncology368 citations Open access
Semantic Scholar
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
A. Eggermont, S. Suciu, R. MacKie, W. Ruka +11 more
2005The Lancet316 citations
Semantic Scholar
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
A. Eggermont, S. Suciu, A. Testori, M. Santinami +11 more
2012Journal of Clinical Oncology258 citations Open access
Semantic Scholar
Side Effects of Interferon-α Therapy
S. Sleijfer, M. Bannink, A. R. Gool, W. Kruit +1 more
2005Pharmacy World & Science247 citations
Semantic Scholar
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
P. Patel, S. Suciu, L. Mortier, W. Kruit +15 more
2011European Journal of Cancer222 citations
Semantic Scholar
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.
W. Kruit, S. Suciu, B. Dréno, L. Mortier +13 more
2013Journal of Clinical Oncology216 citations
Semantic Scholar
Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
H. Schmidt, S. Suciu, C. Punt, M. Gore +6 more
2007Journal of Clinical Oncology198 citations
Semantic Scholar
Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
A. Eggermont, S. Suciu, A. Testori, W. Kruit +11 more
2012European Journal of Cancer191 citations
Semantic Scholar
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients
I. Bleumer, Alexander Knuth, E. Oosterwijk, R. Hofmann +9 more
2004British Journal of Cancer179 citations Open access
Semantic Scholar
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
U. Keilholz, C. Punt, M. Gore, W. Kruit +12 more
2005Journal of Clinical Oncology168 citations Open access
Semantic Scholar
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
B. Dréno, John F. Thompson, B. M. Smithers, M. Santinami +34 more
2018The Lancet Oncology159 citations Open access
Semantic Scholar
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma
W. Kruit, H. H. van Ojik, V. Brichard, B. Escudier +17 more
2005International Journal of Cancer159 citations Open access
Semantic Scholar
Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma.
T. Kivelä, S. Suciu, J. Hansson, W. Kruit +8 more
2003European Journal of Cancer126 citations
Semantic Scholar
EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
A. Eggermont, S. Suciu, M. Santinami, A. Testori +13 more
2008124 citations
Semantic Scholar
IL-12: a promising adjuvant for cancer vaccination
Johanna E. A. Portielje, J. Gratama, H. H. van Ojik, G. Stoter +1 more
2003Cancer Immunology and Immunotherapy118 citations Open access
Semantic Scholar
Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.
A. Jochems, M. Schouwenburg, B. Leeneman, M. Franken +21 more
2017European Journal of Cancer106 citations Open access
Semantic Scholar
Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.
A. Bottomley, C. Coens, S. Suciu, M. Santinami +14 more
2009Journal of Clinical Oncology105 citations
Semantic Scholar
Side effects of interferon-alpha therapy.
S. Sleijfer, M. Bannink, A. V. Van Gool, W. Kruit +1 more
2005Pharmacy World & Science102 citations
Semantic Scholar
Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
J. Kloth, Anna Pagani, M. Verboom, A. Malovini +6 more
2015British Journal of Cancer98 citations Open access
Semantic Scholar
Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.
A. Eggermont, S. Suciu, P. Rutkowski, J. Marsden +13 more
2013Journal of Clinical Oncology91 citations
Semantic Scholar
Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
A. Eggermont, S. Suciu, P. Rutkowski, W. Kruit +6 more
2016European Journal of Cancer86 citations
Semantic Scholar
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
M. Bouwhuis, S. Suciu, S. Collette, S. Aamdal +11 more
2009Journal of the National Cancer Institute80 citations
Semantic Scholar
Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032- 18031)
W. Kruit, S. Suciu, B. Dréno, V. Chiarion-Sileni +6 more
200879 citations
Semantic Scholar
Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-γ, tumor necrosis factor-α, IL-6, and IL-8 responses
Johanna E. A. Portielje, C. Lamers, W. Kruit, A. Sparreboom +4 more
200378 citations
Semantic Scholar
Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.
M. Bouwhuis, S. Suciu, A. Testori, W. Kruit +7 more
2010Journal of Clinical Oncology73 citations
Semantic Scholar
Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses.
Johanna E. A. Portielje, C. Lamers, W. Kruit, A. Sparreboom +4 more
2003Clinical Cancer Research62 citations
Semantic Scholar
Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling
F. Kruiswijk, SC Hasenfuss, R. Sivapatham, MP Baar +11 more
2015Oncogene60 citations Open access
Semantic Scholar
Expression of defined genes identified by pretreatment tumor profiling: Association with clinical responses to the GSK MAGE- A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032–18031)
J. Louahed, O. Gruselle, S. Gaulis, T. Coche +6 more
200860 citations
Semantic Scholar
Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952.
M. Bouwhuis, S. Suciu, W. Kruit, F. Salés +7 more
2011European Journal of Cancer55 citations
Semantic Scholar
Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).
A. Fusi, S. Collette, A. Busse, S. Suciu +9 more
2009European Journal of Cancer50 citations
Semantic Scholar
Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: Second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin
U. Keilholz, P. Martus, C. Punt, W. Kruit +7 more
200250 citations
Semantic Scholar
Neuropsychiatric side effects of interferon‐alfa therapy
A. V. Van Gool, W. Kruit, F. Engels, G. Stoter +2 more
2003Pharmacy World & Science47 citations
Semantic Scholar
Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover
C. Lebbé, C. Dutriaux, T. Lesimple, W. Kruit +16 more
2020Cancers44 citations Open access
Semantic Scholar
Thalidomide in solid tumours: the resurrection of an old drug.
S. Sleijfer, W. Kruit, G. Stoter
2004European Journal of Cancer42 citations
Semantic Scholar
Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients.
A. V. Van Gool, D. Fekkes, W. Kruit, P. Mulder +4 more
2003Psychiatry Research41 citations
Semantic Scholar
Paraneoplastic ophthalmoplegia and subacute motor axonal neuropathy associated with anti-GQ1b antibodies in a patient with malignant melanoma
L. Kloos, P. Smitt, C. W. Ang, W. Kruit +1 more
2003Journal of Neurology Neurosurgery & Psychiatry39 citations Open access
Semantic Scholar
Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?
M. Schouwenburg, K. Suijkerbuijk, R. Koornstra, A. Jochems +16 more
2019Cancers35 citations Open access
Semantic Scholar
Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry
A. Jochems, M. K. van der Kooij, M. Fiocco, M. Schouwenburg +21 more
2019Cancers30 citations Open access
Semantic Scholar
Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant
Johanna E. A. Portielje, W. Kruit, A. Eerenberg, M. Schuler +6 more
2004Cancer Immunology and Immunotherapy30 citations Open access
Semantic Scholar
Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma.
B. Leeneman, M. Franken, V. Coupé, M. Hendriks +7 more
2019European Journal of Surgical Oncology28 citations Open access
Semantic Scholar
EORTC 18991: Long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial
A. Eggermont, S. Suciu, M. Santinami, W. Kruit +6 more
200728 citations
Semantic Scholar
Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy
W. Kruit, G. Stoter, J. Klijn
2004Anti-Cancer Drugs26 citations
Semantic Scholar
Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment.
J. Kloth, P. Hamberg, Pauline A. J. Mendelaar, R. Dulfer +6 more
2016European Journal of Cancer25 citations
Semantic Scholar
EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-α2b (PEG-IFN) versus observation in resected stage III melanoma: Long-term results at 7.6-years follow-up.
A. Eggermont, S. Suciu, M. Santinami, W. Kruit +10 more
2011Journal of Clinical Oncology23 citations
Semantic Scholar
Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)
A. Eggermont, M. Bouwhuis, W. Kruit, A. Testori +3 more
2010Cancer Chemotherapy and Pharmacology23 citations
Semantic Scholar
Regulation of ferritin: a specific role for interferon-alpha (IFN-alpha)? The acute phase response in patients treated with IFN-alpha-2b.
T. Stam, A. Swaak, W. Kruit, A. Eggermont
2002European Journal of Clinical Investigation22 citations
Semantic Scholar
A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients.
Z. Varga, P. D. de Mulder, W. Kruit, A. Hegele +6 more
2003Folia biologica21 citations Open access
Semantic Scholar
Influence of pegylated interferon-α therapy on plasma levels of citrulline and arginine in melanoma patients
Durk Fekkes, M. Bannink, W. Kruit, A. V. Van Gool +4 more
2006Amino Acids19 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Suciu×20
Invite
S. Suciu — researcher profile on SciRah
A. Eggermont×18
Invite
A. Eggermont — researcher profile on SciRah
C. Punt×16
Invite
C. Punt — researcher profile on SciRah
U. Keilholz×16
Invite
U. Keilholz — researcher profile on SciRah

×14

Invite

A. Testori — researcher profile on SciRah

Invite

G. Stoter — researcher profile on SciRah

M. Santinami×11

Invite

M. Santinami — researcher profile on SciRah

Invite

P. Patel — researcher profile on SciRah

Invite

F. Sales — researcher profile on SciRah

Invite

R. Dummer — researcher profile on SciRah

Invite

J. Marsden — researcher profile on SciRah

D. Schadendorf×7

Invite

D. Schadendorf — researcher profile on SciRah